Evotec SE (EVO)
- Previous Close
5.27 - Open
5.24 - Bid 5.11 x 100
- Ask 5.18 x 200
- Day's Range
5.15 - 5.24 - 52 Week Range
4.87 - 13.49 - Volume
31,425 - Avg. Volume
110,911 - Market Cap (intraday)
1.825B - Beta (5Y Monthly) 1.17
- PE Ratio (TTM)
-- - EPS (TTM)
-0.25 - Earnings Date May 22, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.80
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
www.evotec.com5,061
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: EVO
Performance Overview: EVO
Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EVO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EVO
Valuation Measures
Market Cap
1.82B
Enterprise Value
1.83B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.17
Price/Book (mrq)
1.52
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-10.74%
Return on Assets (ttm)
0.03%
Return on Equity (ttm)
-7.27%
Revenue (ttm)
781.43M
Net Income Avi to Common (ttm)
-83.91M
Diluted EPS (ttm)
-0.25
Balance Sheet and Cash Flow
Total Cash (mrq)
604.11M
Total Debt/Equity (mrq)
55.91%
Levered Free Cash Flow (ttm)
-69.81M
Research Analysis: EVO
Company Insights: EVO
EVO does not have Company Insights